Transdermal delivery of the active enantiomer of ketorolac
Patent 5589498 Issued on December 31, 1996. Estimated Expiration Date: June 6, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The invention provides for the transdermal delivery of the active enantiomer of the analgesic ketorolac. Transdermal patches according to the invention are capable of delivering (-) ketorolac to a patient at therapeutically effective levels, at a flux rate of 20 μg/cm2.hr or more. Patches for use in the present invention may be adhesive matrix, monolithic matrix, or liquid reservoir transdermal patches.
Other References
Gusman et al., Chemical Abstracts 104(15): 129734n, 1986
Brocks et al., Medline Abstract No. 93092511, 1992
Yu, et al., "Percutanteous Absorption of Nicardipine and Ketorolac in Rehsus Monkeys," Pharmaceutical Research, vol. 5, No. 7, 1988, pp. 457-462
Greenwald, "Ketorolac: An Innovative Non-Steroidal Analgesic," Drugs of Today, vol. 28, No. 1, 1992, pp. 41-61
Baker, R. W. Controlled Release of Biologically Active Agents, John Wiley & Sons, NY, pp. 4-10 (1987)
Jamali et al. J. of Pharmaceutical Sciences 789 695-714 (1989)
Campbell, D. B. European J. of Drug Metabolism and Pharmacokinetics 15 109-125 (1990)
Guzman, et al. J. Med. Chem. 29 589-591 (1986)
Mroszczak et al. Clin. Pharmacology & Therapeutics 49 126 (1991)
Stinson C&EN 46-79 (Sep. 28, 1992)
Rowland & Tozer Clinical Pharmacokinetics: Concepts and Applications 2nd Ed. (1989) pp. 19-25
June 6, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
